Fisetin: The Strawberry Flavonoid Reshaping Senescent-Cell Research

Fisetin is a naturally occurring flavonol found most abundantly in strawberries (about 160 µg per gram fresh weight), with smaller amounts in apples, persimmons, kiwis, grapes, cucumbers, and onions. Long classified as a garden-variety antioxidant, fisetin has emerged over the past decade as one of the most promising senolytic compounds yet identified — a class of molecules that selectively eliminate senescent cells, the dysfunctional “zombie cells” that accumulate with age and drive chronic inflammation, tissue decline, and many age-related diseases.

This article reviews what senescent cells are, how fisetin targets them, the landmark Mayo Clinic research that reset attention on this obscure flavonoid, current human-trial status, dosing approaches, and the limits of the evidence.

Table of Contents

  1. What Senescent Cells Are — The Zombie Cell Problem
  2. The Mayo Clinic Fisetin Study
  3. Mechanism — How Fisetin Eliminates Senescent Cells
  4. Beyond Senolytics: Antioxidant, Anti-Inflammatory, Neuroprotective
  5. Current Human Trials
  6. Dosing Approaches
  7. Food Sources
  8. Safety and Limits of the Evidence
  9. Connections

What Senescent Cells Are — The Zombie Cell Problem

When cells are damaged beyond repair — through radiation, oxidative stress, DNA damage, or simply repeated division — they enter a state called cellular senescence. They stop dividing but refuse to die, instead secreting a toxic cocktail of inflammatory cytokines, chemokines, and tissue-remodeling enzymes known as the senescence-associated secretory phenotype (SASP). A few senescent cells in a young tissue are harmless. With age, their numbers grow, their SASP output poisons surrounding tissue, and they drive a surprising fraction of age-related disease — arthritis, atherosclerosis, frailty, fibrosis, cognitive decline, and type-2 diabetes. Mouse studies have shown that simply removing senescent cells extends healthspan and reduces multimorbidity.

The Mayo Clinic Fisetin Study

In 2018, a research group led by James Kirkland at the Mayo Clinic screened ten flavonoid compounds for senolytic activity and identified fisetin as the most potent. A single course of fisetin in aged mice reduced senescent-cell burden in multiple tissues, restored tissue homeostasis, and extended median and maximum lifespan. The magnitude — and the fact that it was achieved in already-old animals — captured significant scientific attention and triggered a wave of human trials.

Mechanism — How Fisetin Eliminates Senescent Cells

Senescent cells survive by over-expressing anti-apoptotic proteins — the “SCAPs” (senescent-cell anti-apoptotic pathways). Fisetin inhibits several of these (notably BCL-xL and PI3K/AKT signaling), tipping already-stressed senescent cells into programmed cell death while leaving healthy cells unharmed. This selectivity is what distinguishes senolytics from conventional cytotoxic drugs.

Beyond Senolytics: Antioxidant, Anti-Inflammatory, Neuroprotective

Current Human Trials

Human trials include Mayo Clinic’s Alleviation by Fisetin of Frailty, Inflammation, and Related Measures (AFFIRM) and trials for age-related osteoarthritis, chronic kidney disease, and diabetic kidney disease. Early results have shown reductions in circulating senescent-cell markers and inflammatory cytokines in older adults. Larger efficacy trials remain ongoing.

Dosing Approaches

Most human studies use a pulsed “hit and run” approach — high doses for 2–3 consecutive days, repeated every few weeks or months — rather than daily continuous dosing. This matches the biology: senescent cells take weeks to accumulate, so continuous suppression is unnecessary. Typical research doses are 20 mg/kg body weight per day for two consecutive days, usually taken with fat-containing meals for absorption. Bioavailability is modest; formulations with liposomal encapsulation, phytosomes (e.g., Phytosome fisetin), or co-administration with black pepper piperine aim to address this.

Food Sources

Dietary intake alone does not reach the doses used in trials, but regular strawberry consumption contributes to overall flavonoid status along with its many other nutritional benefits.

Safety and Limits of the Evidence

Fisetin has excellent safety in short-term dosing. Long-term safety in humans at senolytic doses has not been fully characterized. Because it has some antiplatelet activity, caution is reasonable around major surgery and with anticoagulant medications. The field is moving fast but still immature: claims that fisetin is a proven anti-aging therapy are premature, while claims that it is “just another antioxidant” now look dated. A cautious but engaged approach — following trial results, dosing intermittently if at all, and prioritizing the many other longevity levers — is the honest position.

Connections

↑ Back to Table of Contents